

α -Glucosidase Inhibitory Activity of Phenolic Compounds Isolated from the Stems of *Caesalpinia decapetala* var. *japonica*

Thi Thanh Le¹, Manh Tuan Ha¹, Le Minh Hoang¹, Ngoc Khanh Vu¹, Jeong Ah Kim², and Byung Sun Min^{1,*}

¹College of Pharmacy, Drug Research and Development Center, Daegu Catholic University, Gyeongbuk 38430, Republic of Korea

²College of Pharmacy, Research Institute of Pharmaceutical Science, Kyungpook National University, Daegu 41566, Republic of Korea

Abstract – In our study, sixteen known phenolic compounds, including quercetin (**1**), methyl gallate (**2**), caesalpinia-phenol C (**3**), 8*S*,8'*S*,7'*R*-(-)-lyoniresinol (**4**), 7,3',5'-trihydroxyflavanone (**5**), sappanchalcone (**6**), sappanone A (**7**), taxifolin (**8**), fisetin (**9**), fustin (**10**), (+)-catechin (**11**), brazilin (**12**), 3,4,5-trimethoxyphenyl β -D-glucopyranoside (**13**), 1-(2-methylbutyryl)phloroglucinol-glucopyranoside (**14**), (+)-*epi*-catechin (**15**), and astragalol (**16**) and one mixture of two conformers of protosappanin B (**17/18**) were isolated from the stems of *Caesalpinia decapetala* var. *japonica*. Their structures were elucidated based on a comparison of their physicochemical and spectral data with those of literature. To the best of our knowledge, this represents the first isolation of compounds **3**, **4**, **8**, **9**, and **10** from *C. decapetala* and compounds **13** and **14** from the *Caesalpinia* genus. All the isolated compounds were evaluated for their inhibitory effect against the α -glucosidase enzyme. Among them, two flavonols (**1** and **9**), one chalcone (**6**), and one homoisoflavanone (**7**) exhibited an inhibitory effect on α -glucosidase action with an IC₅₀ range value of 5.08 – 15.01 μ M, stronger than that of the positive control (acarbose, IC₅₀ = 152.22 μ M). Kinetic analysis revealed that compounds **1** and **9** showed non-competitive α -glucosidase inhibition, while the inhibition type was mixed for compounds **6** and **7**.

Keywords – *Caesalpinia decapetala* var. *japonica*, Leguminosae, flavonoids, anti-diabetic, α -glucosidase

Introduction

Diabetes, a chronic disease, is a heterogeneous metabolic disorder characterized by elevated blood glucose levels in the body. This disease affects millions of people around the world, causing a variety of life-threatening complications on cardiovascular, neurological, and kidney. Although conventional synthetic medicines are available, they are usually accompanied by serious adverse effects such as gastrointestinal problems disturbances, and metabolic effects.¹ Thus, finding alternative natural medicine is an attractive strategy. The α -glucosidase enzyme hydrolyzes starch and sucrose down to glucose, inducing an increase in postprandial glucose levels in diabetic patients.² Hence, inhibiting the activity of this enzyme produces a massive reduction of postprandial hyperglycemia, and decreases the risk of developing diabetes.³

The *Caesalpinia* genus (Leguminosae family) comprises approximately 100 species and spreads widely in the tropical and subtropical regions of Southeast Asia. *Caesalpinia decapetala* var. *japonica* is located in China, Korea, India, and Malaysia.⁴ Its whole plants had great medicinal values in folk medicine. Seeds of *C. decapetala* var. *japonica* were used for malaria and freckled skin.⁵ Flowers of this plant treat infusion in bronchitis, asthma, and malarial fevers.⁶ Leaves of *C. decapetala* var. *japonica* were used in the treatment of burns, biliousness, and stomach disorders.⁶ Its roots were applied to treat bronchitis, prevent colds, and anti-malarial.⁶ Roots and stems were also used for relieving pain.⁶ *C. decapetala* var. *japonica* contained various chemical components, including essential oils,⁷ flavonoids,^{8,9} chalcones,⁹ terpenoids,^{8,10} and steroids,⁹ which showed beneficial bioactivities such as anti-tumor,⁹ anti-oxidant,⁹ anti-analgesic,⁸ anti-inflammatory,⁸ anti-pyretic,⁸ and anti-virus.¹¹

However, most of the previous phytochemical investigations of *C. decapetala* var. *japonica* focused on its root and leaves,¹²⁻¹⁴ the number of studies on its stems is still limited. Furthermore, although the blood-glucose-lowering

*Author for correspondence

Byung Sun Min, College of Pharmacy, Drug Research and Development Center, Daegu Catholic University, Gyeongbuk 38430, Republic of Korea

Tel: +82-53-850-3613; E-mail: bsmin@cu.ac.kr

effects of leaves and whole plant extract have been demonstrated,^{15,16} this effect of *C. decapetala* var. *japonica* stems and its chemical components have not been reported. Therefore, we herein conducted isolation and structural determination of chemical components from *C. japonica* stem extract, and investigation of their α -glucosidase inhibitory effect aimed to explore the anti-diabetic activity of *C. decapetala* var. *japonica* stems.

Experimental

General experiment procedures – Specific optical rotation was measured using a JASCO P-2000 digital polarimeter (JASCO Corporation, Tokyo, Japan). The 1D and 2D-NMR spectra were obtained on a Varian Unity Inova 400 MHz (Varian, Inc., California, USA) spectrometer with tetramethylsilane (TMS) as an internal standard and the chemical shifts were recorded in δ values (ppm). Silica gel (Merck, 0.040-0.063 mm), RPC-18 (Merck, 17 mesh), and Sephadex LH-20 (Pharmacia Company) were used for column chromatography (CC). High-performance liquid chromatography was carried out on a Waters 2487 controller system with a UV detector (UV/VIS-156). RPC-18 F_{254s} and silica gel F₂₅₄ (Merck) plates were used to perform thin-layer chromatography (TLC). Compounds were detected under UV light and then visualized by heating after spraying with H₂SO₄ 10%.

Chemical and reagents – Yeast α -glucosidase, *p*-nitrophenyl α -D-glucopyranoside (*p*-NPG), sodium phosphate, sodium carbonate, acarbose, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich Co. (St. Louis, MO, U.S.A.).

Plant materials – The stems of *Caesalpinia decapetala* var. *japonica* were collected at Jeju-do, Republic of Korea, in June 2018 and identified by Professor Byung Sun Min. A voucher specimen (CUD-1857-1) was deposited at the Herbarium of the College of Pharmacy, Daegu Catholic University, Korea.

Extraction and isolation – The dried stems of *C. decapetala* var. *japonica* (16.0 kg) were extracted with MeOH (20 L \times 5 times \times 4 h) and then evaporated to dryness to obtain the MeOH extract. The MeOH extract (4.0 kg) was suspended in distilled water (3 L) and then partitioned successively with *n*-hexane, CH₂Cl₂, EtOAc, and *n*-butanol to collect *n*-hexane (715.1 g), CH₂Cl₂ (408.5 g), EtOAc (110.1 g), and *n*-butanol (490.2 g) fractions and a water residue, respectively.

The EtOAc fraction (110.1 g) was chromatographed over a silica gel column (CH₂Cl₂:MeOH, stepwise, 25:1 \rightarrow 0:1) to collect 4 fractions (E1–E4). E2 (15.5 g) was then

separated by a silica gel CC (CH₂Cl₂:MeOH, 20:1) to yield 7 sub-fractions E2.1–E2.7. Fraction E2.4 (3.1 g) was fractionated by a normal phase CC (CH₂Cl₂:MeOH, 25:1) to furnish compound **1** (6.0 mg) and sub-fractions E2.4.1–E3.4.5. E2.4.3 (234.2 mg) was purified by RPC-18 CC (MeOH:H₂O, 1:3) and then Sephadex LH-20 CC (MeOH:H₂O, 1:1) to afford **2** (5.1 mg) and **3** (9.8 mg). By the same method, compounds **4** (9.9 mg), **5** (30.1 mg), and **6** (49.5 mg) were collected from E2.4.4 (345.5 mg), and compounds **7** (6.0 mg) and **8** (50.1 mg) were obtained from E2.4.5 (158.7 mg). Fractionation of E2.6 passed over silica gel CC (CH₂Cl₂:MeOH, 22:1) to yield sub-fractions E2.6.1–E2.6.5. Sub-fraction E2.6.4 (359.7 mg) was subjected to chromatography on a RPC-18 column (MeOH:H₂O, 1:4) and subsequently purified by Sephadex LH-20 CC (MeOH:H₂O, 1:1) to obtain **9** (15.2 mg) and **10** (80.6 mg). Sub-fraction E2.6.5 (390.1 mg) was separated by RPC-18 CC using MeOH:H₂O (1:4) and further purified by a preparative Waters HPLC system (40% MeOH in 5 mL/min, 40 min) to yield **11** (3.0 mg, *t*_R = 28.4 min). Compound **12** (5.1 mg) was afforded from E2.7 (124.6 mg) under the same conditions. E3 (4.5 g) was divided into 8 sub-fractions E3.1–E3.8 by using a silica gel CC (CH₂Cl₂: MeOH, 12:1). Fraction E3.3 (556.7 mg) was continuously separated by a silica gel CC (CH₂Cl₂: MeOH, 10:1) to give 5 sub-fractions E3.3.1–E3.3.5. Sub-fraction E3.3.5 (159.7 mg) was chromatographed over a RPC-18 CC (MeOH:H₂O, 1:3) and then purified by Sephadex LH-20 CC (MeOH:H₂O, 1:2) to furnish **13** (14.5 mg). Fraction E3.7 (631.4 mg) was divided into 3 sub-fractions E3.7.1–E3.7.3 by a silica gel CC (CH₂Cl₂: MeOH, 9:1). Application the same method in case of sub-fraction E2.6.4 for sub-fraction E3.7.2 (324.2 mg), compounds **14** (80.0 mg) and **15** (9.7 mg) were isolated. Similarly, compound **16** (5.0 mg), and a mixture **17/18** (30.1 mg) were afforded from E3.8.3 (250.4 mg).

Quercetin (1) – Amorphous yellow powder; C₁₅H₁₀O₇; ¹H NMR (400 MHz, CD₃OD): δ _H 7.71 (1H, s, H-2'), 7.61 (1H, d, *J* = 8.4 Hz, H-6'), 6.86 (1H, d, *J* = 8.4 Hz, H-5'), 6.36 (1H, s, H-6), 6.16 (1H, s, H-8); ¹³C NMR (100 MHz, CD₃OD): δ _C 175.9 (C-4), 164.2 (C-7), 161.0 (C-5), 156.8 (C-9), 147.3 (C-4'), 146.5 (C-3'), 144.8 (C-2), 135.8 (C-3), 122.7 (C-1'), 120.2 (C-6'), 114.8 (C-5'), 114.6 (C-2'), 103.0 (C-10), 97.8 (C-6), 92.9 (C-8).¹⁷

Methyl gallate (2) – Amorphous white powder; C₈H₈O₅; ¹H NMR (400 MHz, CD₃OD): δ _H 7.02 (2H, s, H-2, 6), 3.79 (3H, s, 7-OCH₃); ¹³C NMR (100 MHz, CD₃OD): δ _C 167.6 (C-7), 145.0 (C-3, 5), 138.3 (C-4), 119.9 (C-1), 108.6 (C-2, 6), 50.8 (7-OCH₃).¹⁸

Caesalpinia phenol C (3) – Yellow needles; C₁₄H₁₀O₅;

^1H NMR (400 MHz, CD_3OD): δ_{H} 7.06 (1H, d, $J = 8.2$ Hz, H-1), 6.68 (2H, s, H-8, 11), 6.66 (1H, dd, $J = 8.4, 1.8$ Hz, H-2), 6.62 (1H, d, $J = 1.8$, H-4), 4.42 (2H, s, H-6); ^{13}C NMR (100 MHz, CD_3OD): δ_{C} 207.7 (C-7), 159.6 (C-3), 159.0 (C-4a), 145.6 (C-9), 145.3 (C-10), 131.8 (C-11a), 130.9 (C-1), 127.1 (C-11b), 124.8 (C-7a), 117.4 (C-8, C-11), 113.3 (C-2), 108.8 (C-4), 78.8 (C-6).¹⁹

(8S,8'S,7'R)-(-)-lyoniresinol (4) – Amorphous white powder; $\text{C}_{22}\text{H}_{28}\text{O}_8$; $\alpha_{\text{D}}^{20} -40$ ($c = 0.025$, MeOH); ^1H NMR (400 MHz, CD_3OD): δ_{H} 6.56 (1H, s, H-2), 6.36 (2H, s, H-2', 6'), 4.29 (1H, d, $J = 5.7$ Hz, H-7'), 3.83 (3H, s, 3-OCH₃), 3.71 (6H, s, 3', 5'-OCH₃), 3.64 (1H, d, $J = 5.5$ Hz, Hb-9'), 3.57 (1H, dd, $J = 10.8, 5.0$ Hz, Hb-9), 3.48 (2H, m, Ha-9', Ha-9), 3.35 (3H, s, 5-OCH₃), 2.68 (1H, dd, $J = 15.0, 4.8$ Hz, Hb-7), 2.55 (1H, dd, $J = 15.0, 11.8$ Hz, Ha-7), 1.95 (1H, dd, $J = 8.1, 5.5$ Hz, H-8'), 1.61 (1H, m, H-8); ^{13}C NMR (100 MHz, CD_3OD): δ_{C} 147.5 (C-3', 5'), 147.2 (C-3), 146.2 (C-5), 137.8 (C-1'), 137.4 (C-4), 133.0 (C-4'), 128.7 (C-1), 124.8 (C-6), 106.3 (C-2), 105.4 (C-2', 6'), 65.3 (C-9), 62.7 (C-9'), 58.7 (5-OCH₃), 55.3 (3-OCH₃), 55.2 (3', 5'-OCH₃), 47.6 (C-8'), 40.9 (C-7'), 39.4 (C-8), 32.1 (C-7).²⁰

7,3',5'-Trihydroxyflavanone (5) – Amorphous white powder; $\text{C}_{15}\text{H}_{14}\text{O}_5$; ^1H NMR (400 MHz, CD_3OD): δ_{H} 7.69 (1H, dd, $J = 8.8, 0.8$ Hz, H-5), 6.91 (1H, s, H-4'), 6.77 (2H, s, H-2', 6'), 6.47 (1H, d, $J = 8.8$ Hz, H-6), 6.33 (1H, d, $J = 1.2$ Hz, H-8), 5.28 (1H, d, $J = 12.8$ Hz, H-2), 2.98 (1H, dd, $J = 16.8, 12.8$ Hz, Ha-3), 2.66 (1H, dd, $J = 16.8, 2.4$ Hz, Ha-3); ^{13}C NMR (100 MHz, CD_3OD): δ_{C} 192.2 (C-4), 165.2 (C-7), 164.1 (C-9), 145.3 (C-5'), 145.0 (C-3'), 130.1 (C-1'), 128.4 (C-5), 117.8 (C-2'), 114.8 (C-6'), 113.5 (C-10), 113.3 (C-4'), 110.3 (C-6), 102.4 (C-8), 79.6 (C-2), 43.5 (C-3).²¹

Sappanchalcone (6) – Amorphous yellow powder; $\text{C}_{16}\text{H}_{14}\text{O}_5$; ^1H NMR (400 MHz, CD_3OD): δ_{H} 7.55 (1H, d, $J = 8.5$ Hz, H-6'), 7.47 (1H, d, $J = 15.6$ Hz, H-7), 7.34 (1H, d, $J = 15.6$ Hz, H-8), 7.09 (1H, s, H-2), 6.96 (1H, d, $J = 8.2$ Hz, H-6), 6.77 (1H, d, $J = 8.2$ Hz, H-5), 6.48 (1H, d, $J = 1.6$ Hz, H-3'), 6.43 (1H, d, $J = 8.5, 1.6$ Hz, H-5'), 3.86 (3H, s, 2'-OCH₃); ^{13}C NMR (100 MHz, CD_3OD): 191.7 (C-9), 163.1 (C-4'), 161.1 (C-2'), 148.1 (C-4), 145.4 (C-3), 143.1 (C-7), 132.3 (C-6'), 127.2 (C-1), 123.7 (C-8), 121.9 (C-6), 120.3 (C-1'), 115.1 (C-5), 113.8 (C-2), 107.5 (C-5'), 98.7 (C-3'), 54.7 (2'-OCH₃).²²

Sappanone A (7) – Amorphous yellow powder; $\text{C}_{16}\text{H}_{12}\text{O}_5$; ^1H NMR (400 MHz, CD_3OD): δ_{H} 7.77 (1H, d, $J = 8.7$ Hz, H-5), 7.62 (1H, s, H-9), 6.84 (1H, d, $J = 8.1$ Hz, H-5'), 6.80 (1H, s, H-2'), 6.74 (1H, d, $J = 8.1$ Hz, H-6'), 6.50 (1H, d, $J = 8.7$ Hz, H-6), 6.28 (1H, s, H-8), 5.33 (2H, s, H-2); ^{13}C NMR (100 MHz, CD_3OD): 181.6 (C-4),

165.1 (C-7), 163.4 (C-8a), 147.3 (C-3'), 145.1 (C-4'), 137.0 (C-9), 129.2 (C-5), 128.0 (C-1'), 126.2 (C-3), 123.1 (C-6'), 116.9 (C-5'), 115.1 (C-2'), 114.5 (C-4a), 110.7 (C-6), 102.2 (C-8), 67.7 (C-2).²³

Taxifolin (8) – Amorphous colorless powder; $\text{C}_{15}\text{H}_{12}\text{O}_7$; ^1H NMR (400 MHz, CD_3OD): δ_{H} 6.95 (1H, d, $J = 1.5$ Hz, H-2), 6.83 (1H, dd, $J = 8.1, 1.5$ Hz, H-6), 6.78 (1H, d, $J = 8.1$ Hz, H-5'), 5.90 (1H, d, $J = 1.5$ Hz, H-8), 5.86 (1H, d, $J = 1.5$ Hz, H-6), 4.87 (1H, d, $J = 11.5$ Hz, H-2), 4.48 (1H, d, $J = 11.5$ Hz, H-3); ^{13}C NMR (100 MHz, CD_3OD): δ_{C} 196.9 (C-4), 167.3 (C-7), 163.8 (C-5), 163.0 (C-9), 145.7 (C-4'), 144.8 (C-3'), 128.4 (C-1'), 119.6 (C-6'), 114.7 (C-5'), 114.5 (C-2'), 100.4 (C-10), 95.9 (C-6), 94.9 (C-8), 83.6 (C-2), 72.2 (C-3).²⁴

Fisetin (9) – Amorphous white powder; $\text{C}_{15}\text{H}_{10}\text{O}_7$; ^1H NMR (400 MHz, CD_3OD): δ_{H} 7.96 (1H, dd, $J = 9.4, 0.5$ Hz, H-5), 7.75 (1H, d, $J = 2.1$ Hz, H-2'), 7.65 (1H, ddd, $J = 8.5, 2.1, 0.5$ Hz, H-6'), 6.88 (3H, m, H-6, H-8, H-5'); ^{13}C NMR (100 MHz, CD_3OD): δ_{C} 172.9 (C-4), 162.9 (C-7), 157.1 (C-9), 147.2 (C-4'), 146.0 (C-3'), 144.8 (C-2), 137.1 (C-3), 126.0 (C-5), 122.9 (C-1'), 120.2 (C-6'), 114.8 (C-5'), 114.5 (C-6), 114.5 (C-2'), 113.9 (C-10), 101.5 (C-8).²⁵

Fustin (10) – White needles; $\text{C}_{15}\text{H}_{12}\text{O}_6$; ^1H NMR (400 MHz, CD_3OD): δ_{H} 7.69 (1H, d, $J = 8.7$ Hz, H-5), 6.97 (1H, d, $J = 1.9$ Hz, H-2'), 6.84 (1H, dd, $J = 8.1, 1.9$ Hz, H-6'), 6.79 (1H, d, $J = 8.1, 1.5$ Hz, H-5'), 6.50 (1H, dd, $J = 8.7, 2.2$ Hz, H-6), 6.31 (1H, d, $J = 2.2$ Hz, H-8), 4.92 (1H, d, $J = 11.8$ Hz, H-2), 4.46 (1H, d, $J = 11.8$ Hz, H-3); ^{13}C NMR (100 MHz, CD_3OD): δ_{C} 193.1 (C-4), 165.4 (C-7), 163.6 (C-9), 145.6 (C-3'), 144.8 (C-4'), 128.7 (C-10), 128.6 (C-5), 119.5 (C-6'), 114.7 (C-2'), 114.5 (C-5'), 111.9 (C-10), 110.7 (C-6), 102.3 (C-8), 84.2 (C-2), 73.1 (C-3).²⁶

(+)-Catechin (11) – Colorless solid; $\text{C}_{15}\text{H}_{14}\text{O}_6$; ^1H NMR (400 MHz, CD_3OD): δ_{H} 6.83 (1H, d, $J = 1.9$ Hz, H-2'), 6.75 (1H, d, $J = 8.1$ Hz, H-5'), 6.70 (1H, dd, $J = 8.1, 1.9$ Hz, H-6'), 5.93 (1H, d, $J = 1.8, 1.5$ Hz, H-6), 5.86 (1H, d, $J = 1.8$ Hz, H-8), 4.56 (1H, d, $J = 7.5$ Hz, H-2), 3.97 (1H, dd, $J = 7.5, 5.5$ Hz, H-3), 2.83 (1H, dd, $J = 16.1, 5.5$ Hz, Ha-4), 2.50 (1H, dd, $J = 16.1, 8.1$ Hz, Hb-4); ^{13}C NMR (100 MHz, CD_3OD): δ_{C} 156.3 (C-7), 156.1 (C-5), 155.4 (C-9), 144.8 (C-4'), 144.8 (C-3'), 130.8 (C-1'), 118.7 (C-6'), 114.8 (C-5'), 114.8 (C-2'), 99.5 (C-10), 94.9 (C-6), 94.2 (C-8), 81.4 (C-2), 67.4 (C-3), 27.0 (C-4).²⁷

Brazilin (12) – Amorphous red powder; $\text{C}_{16}\text{H}_{14}\text{O}_5$; ^1H NMR (400 MHz, CD_3OD): δ_{H} 7.17 (1H, d, $J = 8.3$ Hz, H-5), 6.69 (1H, s, H-2'), 6.58 (1H, s, H-5'), 6.45 (1H, dd, $J = 8.3, 2.4$ Hz, H-6), 6.28 (1H, d, $J = 2.4$ Hz, H-8), 3.95 (1H, s, H-4), 3.91 (1H, d, $J = 11.4$ Hz, Ha-2), 3.67 (1H, d, $J = 11.4$ Hz, Hb-2), 3.00 (1H, d, $J = 15.6$ Hz, Ha-9), 2.75 (1H, d, $J = 15.6$ Hz, Hb-9); ^{13}C NMR (100 MHz, CD_3OD):

δ_C 157.8 (C-7), 155.7 (C-8a), 145.6 (C-3'), 145.3 (C-4'), 137.4 (C-6'), 132.2 (C-5), 131.3 (C-1'), 115.5 (C-4a), 112.8 (C-2'), 112.4 (C-5'), 109.9 (C-6), 104.3 (C-8), 78.1 (C-3), 70.8 (C-2), 51.0 (C-4), 42.9 (C-9).²⁸

3,4,5-Trimethoxyphenyl β -D-glucopyranoside (13) – Amorphous white powder; $C_{15}H_{22}O_9$; 1H NMR (400 MHz, DMSO- d_6): δ_H 6.35 (2H, s, H-2, H-6), 4.74 (1H, d, $J=7.4$ Hz, H-1'), 3.70 (6H, s, 3,5-OCH₃), 3.55 (3H, s, 4-OCH₃), 3.04–3.41 (m, H-2'–6'); ^{13}C NMR (100 MHz, DMSO- d_6): δ_C 154.4 (C-1), 153.5 (C-3, 5), 132.8 (C-4), 101.4 (C-1'), 94.7 (C-2, 6), 77.7 (C-5'), 77.2 (C-3'), 73.7 (C-2'), 70.5 (C-4'), 61.3 (C-6'), 60.5 (4-OCH₃), 56.1 (3, 5-OCH₃).²⁹

1-(2-Methylbutyryl)phloroglucinol-glucopyranoside (14) – Amorphous white powder; $C_{17}H_{24}O_9$; 1H NMR (400 MHz, CD₃OD): δ_H 6.16 (1H, d, $J=2.0$ Hz, H-6), 5.94 (1H, d, $J=2.0$ Hz, H-4), 5.02 (1H, d, $J=7.5$ Hz, H-1''), 3.88 (2H, m, H-2', Ha-6''), 3.70 (1H, dd, $J=12.1, 5.4$ Hz, Hb-6''), 3.35–3.50 (4H, m, H-2''–5''), 1.79 (1H, dt, $J=14.2, 7.4$ Hz, Hb-3'), 1.37 (1H, dt, $J=14.2, 7.4$ Hz, Ha-3'), 1.11 (3H, d, $J=6.7$ Hz, H-5'), 0.87 (3H, t, $J=7.4$ Hz, H-4'); ^{13}C NMR (100 MHz, CD₃OD): δ_C 211.7 (C-1'), 167.4 (C-3), 165.8 (C-5), 161.7 (C-1), 106.7 (C-2), 101.6 (C-1''), 98.3 (C-4), 95.4 (C-6), 78.7 (C-5''), 78.4 (C-3''), 74.8 (C-2''), 71.2 (C-4''), 62.5 (C-6''), 46.9 (C-2'), 28.2 (C-3'), 16.8 (C-5'), 12.0 (C-4').³⁰

(+)-Epi-catechin (15) – Colorless solid; $C_{15}H_{14}O_6$; 1H NMR (400 MHz, CD₃OD): δ_H 6.95 (1H, d, $J=1.9$ Hz, H-2'), 6.75 (1H, dd, $J=8.1, 1.9$ Hz, H-6'), 6.74 (1H, d, $J=8.1$ Hz, H-5'), 5.92 (1H, d, $J=1.9$ Hz, H-6), 5.90 (1H, d, $J=1.9$ Hz, H-8), 4.79 (1H, s, H-2), 4.15 (1H, br s, H-3), 2.84 (1H, dd, $J=16.7, 4.5$ Hz, Ha-4), 2.71 (1H, dd, $J=16.7, 2.8$ Hz, Hb-4); ^{13}C NMR (100 MHz, CD₃OD): δ_C 156.5 (C-7), 156.2 (C-5), 155.9 (C-9), 144.5 (C-4'), 144.3 (C-3'), 130.8 (C-1'), 117.9 (C-6'), 114.5 (C-5'), 113.9 (C-2'), 99.6 (C-10), 94.9 (C-6), 94.5 (C-8), 78.4 (C-2), 66.0 (C-3), 27.8 (C-4).²⁷

Astragalol (16) – Amorphous yellow powder; $C_{21}H_{20}O_{11}$; 1H NMR (400 MHz, CD₃OD): δ_H 8.07 (2H, d, $J=8.9$ Hz, H-2', 6'), 6.87 (2H, d, $J=8.9$ Hz, H-3', 5'), 6.39 (1H, d, $J=2.1$ Hz, H-6), 6.19 (1H, d, $J=2.1$ Hz, H-8), 5.13 (1H, d, $J=7.8$ Hz, H-1''), 3.42–3.80 (6H, H-2''–6''). ^{13}C NMR (100 MHz, CD₃OD): δ_C 179.7 (C-4), 166.1 (C-7), 163.1 (C-5), 161.6 (C-4'), 159.1 (C-2), 158.5 (C-9), 135.6 (C-3), 132.4 (C-2', 6'), 122.7 (C-1'), 116.1 (C-3', 5'), 105.7 (C-10), 104.9 (C-1''), 99.9 (C-6), 94.8 (C-8), 77.1 (C-3''), 75.0 (C-5''), 73.0 (C-2''), 70.0 (C-4''), 61.9 (C-6'').³¹

Mixture of two conformers of protosappanin B (17/18) – Colorless solid; $C_{16}H_{16}O_6$.

Major form of protosappanin B (17): 1H NMR (400

MHz, CD₃OD): δ_H 6.96 (d, $J=8.0$ Hz, H-1), 6.72 (ovl, H-9, 12), 6.53 (ovl, H-2), 6.44 (s, H-4), 4.14 (d, $J=12.4$ Hz, Ha-6), 3.85 (d, $J=12.4$ Hz, Hb-6), 3.53 (ovl, Ha-7a), 3.45 (d, $J=11.2$ Hz, Hb-7a), 2.54 (d, $J=13.6$ Hz, Ha-8), 2.48 (d, $J=13.6$ Hz, Hb-8). ^{13}C NMR (100 MHz, CD₃OD): δ_C 159.3 (C-4a), 158.9 (C-3), 144.9 (C-10, 11), 133.2 (C-1), 132.5 (C-12a), 127.5 (C-8a), 124.1 (C-12b), 119.9 (C-9), 117.5 (C-12), 111.5 (C-2), 108.2 (C-4), 76.7 (C-6), 73.0 (C-7), 68.4 (C-7a), 39.9 (C-8).³²

Minor form of protosappanin B (18): 1H NMR (400 MHz, CD₃OD): δ_H 6.96 (d, $J=8.0$ Hz, H-1), 6.72 (ovl, H-9), 6.66 (s, H-12), 6.53 (ovl, H-2), 6.50 (s, H-4), 4.37 (d, $J=12.0$ Hz, Ha-6), 3.53 (ovl, Hb-6, Ha-7a), 3.39 (d, $J=11.2$ Hz, Hb-7a), 2.67 (s, H-8). ^{13}C NMR (100 MHz, CD₃OD): δ_C 160.4 (C-4a), 159.0 (C-3), 144.8 (C-10), 144.8 (C-11), 132.7 (C-1), 132.0 (C-12a), 128.1 (C-8a), 125.2 (C-12b), 119.0 (C-9), 117.9 (C-12), 112.1 (C-2), 108.8 (C-4), 76.7 (C-6), 73.3 (C-7), 65.7 (C-7a), 42.7 (C-8).³²

α -Glucosidase inhibition assay – α -Glucosidase inhibitory assay was conducted spectrophotometrically using *p*-nitrophenyl α -D-glucopyranoside (*p*-NPG) as the substrate, according to the previously published procedure with a slight modification.³³ In brief, 20 μ L enzyme α -glucosidase (0.1 unit) was added to 96 well plates, which contained 20 μ L samples and 20 μ L phosphate buffer (100 mM, pH = 6.8). Subsequently, the enzyme reaction was started by the addition of 20 μ L *p*-NPG (2.5 mM) and then incubated for 10 min at 37°C. After 10 min, 80 μ L Na₂CO₃ 0.2 M was used for each well to finalize the enzyme reaction. The absorbance was measured at 405 nm using a microplate spectrophotometer. Acarbose was used as a positive control. The percentage inhibition (%) is calculated using the following equation:

$$\text{Inhibition (\%)} = (A_c - A_s) / A_c \times 100$$

In which A_c and A_s are the average value of control and sample, respectively.

Enzyme kinetics of α -glucosidase inhibition – To determine the mode of α -glucosidase inhibition of the most active compounds (**1**, **6**, **7**, and **9**), two kinetic methods including Lineweaver-Burk plots and Dixon plots were used.³³ The α -glucosidase inhibition was monitored at various concentrations of substrate *p*-NPG (0.625, 1.25, and 2.5 mM) and different concentrations of tested compounds (1.71, 4.44, and 8.41 μ M for **1**; 3.0, 7.0, and 25.0 μ M for **6**; 8.0, 16.0, and 26.0 μ M for **7**; 5.0, 10.0, and 25.0 μ M for **9**). The enzyme reaction was carried out as described above. The obtained results were analyzed by using SigmaPlot 12.0 software (SPCC Inc, Chicago IL, U.S.A). Kinetic constant values (K_i) were calculated

due to the Dixon plots.

Statistical analysis – All experimental bioassay data were performed as the mean \pm standard error (SE) of the mean from at least three independent experiments. One-way analysis of variance (ANOVA) and Dunnett's test were applied to evaluate statistical significance. *P* values of less than 0.05 were considered to be statistically significant.

Result and Discussion

Phytochemical investigation of *C. decapetala* var. *japonica* stems resulted in the isolation of 16 known compounds (1–16) (Fig. 1), which were identified as quercetin (1),¹⁷ methyl gallate (2),¹⁸ caesalpiniaphenol C (3),¹⁹ 8*S*,8'*S*,7'*R*-(–)-lyoniresinol (4),²⁰ 7,3',5'-trihydroxyflavanone (5),²¹ sappanchalcone (6),²² sappanone A (7),³⁴ taxifolin (8),²⁴ fisetin (9),²⁵ fustin (10),²⁶ (+)-catechin (11),²⁷ brazilin (12),²⁸ 3,4,5-trimethoxyphenyl β -D-glucopyranoside (13),²⁹ 1-(2-methylbutyryl)phloroglucinol-

glucopyranoside (14),³⁰ (+)-*epi*-catechin (15),²⁷ and astragalin (16)³¹, and a mixture of two conformers of protosappanin B (17/18),³² by analyzing and comparing their spectroscopic data with those reported in the literature. Among them, caesalpiniaphenol C (3), 8*S*,8'*S*,7'*R*-(–)-lyoniresinol (4), taxifolin (8), fisetin (9), and fustin (10) were isolated from *C. decapetala* for the first time. In addition, this represents the first isolation of 3,4,5-trimethoxyphenyl β -D-glucopyranoside (13) and 1-(2-methylbutyryl) phloroglucinol-glucopyranoside (14) from the *Caesalpinia* genus.

Compound 3 was obtained as a yellow needle. The ¹H and ¹³C NMR spectra of 3 showed one aromatic ABX system at [δ_H/δ_C 7.06 (1H, d, *J* = 8.4 Hz, H-1)/130.9 (C-1), 6.66 (1H, dd, *J* = 8.4, 1.8 Hz, H-2)/113.3 (C-2), and 6.62 (1H, d, *J* = 1.8 Hz, H-4)/108.8 (C-4)], one 1,2,4,5-tetrasubstituted benzene ring assigned at δ_H/δ_C 6.68 (2H, s, H-8, 11)/117.4 (C-8, 11). It also displayed one methylene group at δ_H/δ_C 4.42 (2H, s, H₂-6)/78.8 (C-6). Besides, the ¹³C NMR spectrum of 3 exhibited one carbonyl carbon signal at δ_C 207.7 (C-7). The NMR data of 3 closely




Fig. 1. Chemical structures of the isolated compounds (1–18).




Fig. 2. Key HMBC and ^1H - ^1H COSY correlations of compounds **3** and **4**.

resembled those of caesalpiniaphenol C reported in the literature.¹⁹ The complete structure of **3** was further determined by the key HMBC correlations of H-6/C-4a, H-6/C-7, H-6/C-7a, H-8/C-7, H-1/C-11a, H-11/C-11a, H-2/C-11b, and H-11/C-11b (Fig. 2). Therefore, **3** was determined to be caesalpiniaphenol C.¹⁹

Compound **4** was obtained as an amorphous, white powder with a negative optical rotation [α_{D}^{20} -40 ($c = 0.025$, MeOH)]. The ^1H and ^{13}C NMR spectra of **4** displayed typical signals for a 4-aryltetralin type lignan, which revealed one 1,2,3,4,5-pentasubstituted benzene ring at [$\delta_{\text{H}}/\delta_{\text{C}}$ 6.56 (1H, s, H-2)/106.3 (C-2)], one 1,3,4,5-tetrasubstituted ring at [$\delta_{\text{H}}/\delta_{\text{C}}$ 6.36 (2H, s, H-2', 6')/105.4 (C-2', 6')], four aromatic methoxy groups at [$\delta_{\text{H}}/\delta_{\text{C}}$ 3.83 (3H, s, 3-OCH₃)/55.3 (3-OCH₃), 3.35 (3H, s, 5-OCH₃)/58.7 (5-OCH₃), 3.71 (6H, s, 3', 5'-OCH₃)/55.2 (3', 5'-OCH₃)], two oxygenated methylene groups at [$\delta_{\text{H}}/\delta_{\text{C}}$ 3.48 (2H, m, Ha-9, Ha-9'), 3.57 (1H, dd, $J = 10.8, 5.0$ Hz, Hb-9), 3.64 (1H, d, $J = 5.5$ Hz, Hb-9')/65.3 (C-9), 62.7 (C-9')], one methylene signal at [$\delta_{\text{H}}/\delta_{\text{C}}$ 2.55 (1H, dd, $J = 15.0, 11.8$ Hz, Ha-7), 2.68 (1H, dd, $J = 15.0, 4.8$ Hz, Hb-7)/32.1 (C-7)], and three methine groups at [$\delta_{\text{H}}/\delta_{\text{C}}$ 4.29 (1H, d, $J = 5.7$ Hz, H-7')/40.9 (C-7'), 1.95 (1H, dd, $J = 8.1, 5.5$ Hz, H-8')/47.6 (C-8'), 1.61 (1H, m, H-8)/39.4 (C-8)]. Based on the above 1D NMR data together with the analysis of the HMQC and HMBC data (Fig. 2), **4** was determined to be lyoniresinol.²⁰ Consequently, the absolute configuration of **4** was identified as 8*S*,8'*S*,7'*R*-($-$)-lyoniresinol based on these observations and comparison with its reported literature.²⁰

Compound **8** was obtained as an amorphous colorless powder. The ^1H and ^{13}C NMR spectra of **8** showed resonances characteristic of a flavanonol with signals of one ABX coupling system at [δ_{H} 6.95 (1H, d, $J = 1.5$ Hz, H-2'), 6.78 (1H, d, $J = 8.1$ Hz, H-5'), 6.83 (1H, dd, $J = 8.1, 1.5$ Hz, H-6')], one 1,2,3,5-tetrasubstituted ring, which was supported by two *meta* coupling protons at [δ_{H} 5.86 (1H, d, $J = 1.5$ Hz, H-6), 5.90 (1H, d, $J = 1.5$ Hz, H-8)], two oxygenated methine protons at δ_{H} 4.87 (1H, d, $J = 11.5$ Hz, H-2), 4.48 (1H, d, $J = 11.5$ Hz, H-3), and one

carbonyl carbon signal at δ_{C} 196.9 (C-4). The ^{13}C NMR spectrum of **8** revealed 15 carbon signals corresponding to the predicted structure. Thus, the chemical structure of **8** was established to be taxifolin.²⁴

Compound **9** was obtained as an amorphous white powder. The ^1H NMR spectrum of **9** displayed signals of two ABX coupling systems at δ_{H} 7.96 (1H, dd, $J = 9.4, 0.5$ Hz, H-5), 6.88 (3H, m, H-6, H-8, H-5'), 7.75 (1H, d, $J = 2.1$ Hz, H-2'), 7.65 (1H, ddd, $J = 8.5, 2.1, 0.5$ Hz, H-6'). Its ^{13}C NMR spectrum exhibited 15 carbon signals, including 12 carbon signals for two substituted benzene rings at δ_{C} 126.0 (C-5), 114.5 (C-6), 162.9 (C-7), 101.5 (C-8), 157.1 (C-9), 113.9 (C-10), 122.9 (C-1'), 114.5 (C-2'), 146.0 (C-3'), 147.2 (C-4'), 114.8 (C-5'), 120.2 (C-6'), two oxygenated olefinic carbon signals at δ_{C} 144.8 (C-2), and 137.1 (C-3), and one carbonyl signal at δ_{C} 172.9 (C-4). Based on a comparison of the above 1D NMR data with those in the literature,²⁵ **9** was determined as a flavonol (fisetin).

Compound **10** was obtained as a white needle. The proton and carbon spectra of **10** were similar to those of **8** except for the signals belonging to ring A with one ABX coupling system at [$\delta_{\text{H}}/\delta_{\text{C}}$ 7.69 (1H, d, $J = 8.7$ Hz, H-5)/128.6 (C-5), 6.50 (1H, dd, $J = 8.7, 2.2$ Hz, H-6)/110.7 (C-6), 6.31 (1H, d, $J = 2.2$ Hz, H-8)/102.3 (C-8)], in **10**. In the comparison with the previous report, **10** was identified to be fustin.²⁶

Compound **13** was obtained as a white powder. The proton spectrum of **13** showed two singlet proton signals for two symmetric protons belonging to one 1,3,4,5-tetrasubstituted benzene ring at δ_{H} 6.35 (2H, s, H-2, H-6), and three aromatic methoxy groups at δ_{H} 3.70 (6H, s, 3, 5-OCH₃), and 3.55 (3H, s, 4-OCH₃). In addition, an anomeric proton signal with a large J coupling constant was observed at δ_{H} 4.74 (1H, d, $J = 7.4$ Hz, H-1'). The β -glucose moiety was further confirmed by the ^{13}C NMR spectrum with 6 typical carbon signals at δ_{C} 101.4 (C-1'), 73.7 (C-2'), 77.2 (C-3'), 70.5 (C-4'), 77.7 (C-5'), and 61.3 (C-6'). The position of glucose moiety was located at C-1 (δ_{C} 154.4) due to the HMBC correlation between anomeric proton H-1' and C-1. Therefore, **13** was established as 3,4,5-trimethoxyphenyl β -D-glucopyranoside.²⁹

Compound **14** was obtained as an amorphous white powder. The ^1H NMR spectrum of **14** showed the aliphatic signals for a 2-methylbutyryl moiety at [δ_{H} 1.37 (1H, dt, $J = 14.2, 7.4$ Hz, Ha-3'), 1.79 (1H, dt, $J = 14.2, 7.4$ Hz, Hb-3'), 0.87 (3H, t, $J = 7.4$ Hz, H-4'), 1.11 (3H, d, $J = 6.7$ Hz, H-5')],³⁰ and an anomeric proton at δ_{H} 5.02 (1H, d, $J = 7.5$ Hz, H-1'). Besides, two *meta*-coupled doublets appeared at δ_{H} 5.94 (1H, d, $J = 2.0$ Hz, H-4), 6.16 (1H, d,

$J = 2.0$ Hz, H-6), indicating an asymmetrically substituted ring. The glucose moiety was attached to δ_C 161.7 (C-1), which was confirmed by the HMBC cross-peaks between H-1" and C-1. Therefore, **14** was determined to be 1-(2-methylbutyryl)phloroglucinol-glucofuranoside.³⁰

The isolated compounds were evaluated for their inhibitory effect against α -glucosidase enzyme with acarbose was used as a positive control ($IC_{50} = 152.22 \pm 1.86 \mu\text{M}$). Our results showed that the isolated flavonols, quercetin (**1**), and fisetin (**9**) exhibited a potent inhibitory effect, presenting IC_{50} values of $5.80 \pm 0.25 \mu\text{M}$ and $10.82 \pm 0.19 \mu\text{M}$, respectively, which were much lower than acarbose (Fig. 3). While astragalinalin (**16**), a flavonol glycoside suppressed slightly α -glucosidase enzyme action ($IC_{50} > 50 \mu\text{M}$) (Table 1). The chalcone **6** (sappanchalcone) and homoisoflavanone **7** (sappanone A) showed a significant α -glucosidase inhibitory activity with IC_{50} values of $15.01 \pm 0.34 \mu\text{M}$ and $14.13 \pm 0.27 \mu\text{M}$, respectively. The isolated flavanone **5** (7,3',5'-trihydroxyflavanone) and flavan-3-ol **15** (*epi*-catechin) exhibited an inhibitory effect of α -glucosidase with IC_{50} values of $22.56 \pm 0.54 \mu\text{M}$ and $30.85 \pm 0.40 \mu\text{M}$, respectively. Besides, caesalpinaphenol C (**3**), and the mixture (**17/18**) also suppressed α -glucosidase action with IC_{50} values of $34.82 \pm 0.25 \mu\text{M}$ and $49.51 \pm 0.06 \mu\text{M}$, respectively. The remaining compounds (**2-4**, **8**, **10-14**) exhibited a weak effect on the inhibition of α -glucosidase ($IC_{50} > 50 \mu\text{M}$) (Table 1).




Fig. 3. Inhibitory effects (%) of the active compounds (**1**, **3**, **5**, **6**, **7**, **9**, **15**, and **17/18**) and acarbose on the enzymatic activities of α -glucosidase at a concentration of $50 \mu\text{M}$. The data are expressed as mean \pm SE. The experiments were done in triplicates.

For the potent inhibitors (**1**, **6**, **7**, and **9**), we continuously examined their inhibition kinetics *in vitro*. α -Glucosidase was treated individually with four concentrations of tested compounds, using *p*-NPG as a substrate ($0.625 - 2.5 \text{ mM}$). The type of inhibition and inhibition constants (K_i values) of the above compounds was deduced from two kinetic methods: Lineweaver-Buck plots and Dixon plots (Fig. 4). After analysis of these two types of graphs and based on the best fit results and goodness to fit analysis, we concluded that two flavonols (**1** and **9**) (Fig.

Table 1. α -Glucosidase inhibitory activity of compounds (**1-18**) and their inhibition type

Compounds	IC_{50} (μM)	Inhibition type	K_i (μM)
1	5.80 ± 0.25	noncompetitive	5.8
2	>50		
3	34.82 ± 0.25		
4	>50		
5	22.56 ± 0.54		
6	15.01 ± 0.34	mixed	11.8
7	14.13 ± 0.27	mixed	8.0
8	>50		
9	10.82 ± 0.19	noncompetitive	10.8
10	>50		
11	>50		
12	>50		
13	>50		
14	>50		
15	30.85 ± 0.40		
16	>50		
17/18	49.51 ± 0.06		
Acarbose ^a	152.22 ± 1.86		

^aPositive control. These data were expressed as the mean \pm SE of triplicate experiments.




Fig. 4. The inhibition kinetics of compounds **1**, **6**, **7**, and **9** towards α -glucosidase. (A–D) Lineweaver-Burk plots for α -glucosidase inhibition of compounds **1** (A), **6** (B), **7** (C), and **9** (D). (E–H) Dixon plots for α -glucosidase inhibition of compounds **1** (E), **6** (F), **7** (G), and **9** (H).

4A and 4D) showed a non-competitive inhibition type with K_i values of 5.8 and 10.8 μM , respectively, while chalcone (**6**) and homoisoflavanone (**7**) (Fig. 4B and 4C) had shown a mixed inhibition type with K_i values of 11.8 and 8.0 μM , respectively. The K_i values were calculated using Dixon plot by plotting the reciprocal of maximum velocity ($1/V_{max}$) (y -axis) against the concentrations (x -axis) (Fig. 4E–H).

Interestingly, two flavonols (**1** and **9**), which contained one carbonyl carbon and one double bond at the C-ring inhibited strongly α -glucosidase enzyme action. The absence of both these characteristics at the C-ring in the case of flavan-3-ols (**11** and **15**), or the lack of a double bond at C-2 in the C ring in the case of flavanone (**5**) and flavanonols (**8** and **10**) induced a significant reduction in the level of inhibition. Meanwhile, the addition of one glucose moiety at C-3 in the structure of **16** also decreased dramatically its inhibitory activity. This evidence supported the key role of flavones in anti-diabetic drug research. Our findings for α -glucosidase inhibitory activity of compounds **1**, **5**, **6**, **9**, **15**–**18** were in accordance with those previously reported.^{35,36} On the other hand, this is the first report on inhibiting α -glucosidase action for caesalpiniafenol C (**3**) and sappanone A (**7**). Furthermore, the α -glucosidase enzyme kinetic inhibition types of sappanchalcone (**6**) and sappanone A (**7**) were also investigated for the first time.

In summary, sixteen known phenolic compounds and one known mixture were isolated from the *C. decapetala* var. *japonica* stems. Five compounds (**3**, **4**, **8**, **9**, and **10**) were reported from this plant for the first time, and two compounds (**13** and **14**) were found in this genus for the first time. Our research concluded that *C. decapetala* var. *japonica* and its flavonoids, especially flavonols, homoisoflavanone, and chalcones were considered to be alternative inhibitors for the regulation of hyperglycemia.

Acknowledgments

This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (2021R1A2C2011940), Korea. We are thankful to the Korea Basic Science Institute (KBSI) for mass spectrometric measurements.

References

- (1) Lago, R. M.; Singh, P. P.; Nesto, R. W. *Nat. Clin. Pract. Endocrinol. Metab.* **2007**, *3*, 667.
- (2) Van de Laar, F. A.; Lucassen, P. L. B. J.; Akkermans, R. P.; Van de Lisdonk, E. H.; Rutten, G. E. H. M.; Van Weel, C. *Cochrane Database Syst. Rev.* **2005**. CD003639.
- (3) Poovitha, S.; Parani, M. *BMC Complement Altern. Med.* **2016**, *16*, 185.
- (4) Tu, W. C.; Ding, L. F.; Peng, L. Y.; Song, L. D.; Wu, X. D.; Zhao, Q. S. *Phytochemistry* **2022**, *193*, 112973.
- (5) Shah, G. M.; Jamal, Z.; Hussain, M. *Pak. J. Bot.* **2013**, *45*, 253-261.
- (6) Chaudhary, C. M.; Jan, H. A.; Kunwar, R. M.; Bussmann, R. W.; Paniagua-Zambrana, N. Y. In *Ethnobotany of the Himalayas: Caesalpinia decapetala* (Roith) Alston Fabaceae; Bussmann, R. W.; Paniagua-Zambrana, N. Y. Ed; Springer International Publishing; **2020**, pp 1-8.
- (7) Miyazawa, M.; Nagata, T.; Nakahashi, H.; Takahashi, T. *J. Essent. Oil Res.* **2012**, *24*, 441-446.
- (8) Parveen, A.; Akash, M. S. H.; Rehman, K.; Mahmood, Q.; Qadir, M. I. *BioImpacts. BI* **2014**, *4*, 43-48.
- (9) Wei, X. H.; Yang, S. J.; Liang, N.; Hu, D. Y.; Jin, L. H.; Xue, W.; Yang, S. *Molecules* **2013**, *18*, 1325-1336.
- (10) Kamikawa, S.; Oshimo, S.; Ohta, E.; Nehira, T.; Ômura, H.; Ohta, S. *Phytochemistry* **2016**, *121*, 50-57.
- (11) Zhang, L.; Chen, J.; Ke, C.; Zhang, H.; Zhang, S.; Tang, W.; Liu, C.; Liu, G.; Chen, S.; Hu, A.; Sun, W.; Xiao, Y.; Liu, M.; Chen, X. *Viruses* **2020**, *12*, 557.
- (12) Ogawa, K.; Aoki, I.; Sashida, Y. *Phytochemistry* **1992**, *31*, 2897-2898.
- (13) Van Kiem, P.; Van Minh, C.; Huong, H. T.; Lee, J. J.; Kim, Y. H. *Chem. Pharm. Bull(Tokyo)*. **2005**, *53*, 428-430.
- (14) Wei, X. H.; Yang, S. J.; Liang, N.; Hu, D. Y.; Jin, L. H.; Xue, W.; Yang, S. *Molecules* **2013**, *18*, 1325-1336.
- (15) Hussain, L.; Qadir, M. I.; Rehman, S. *Bangladesh J. Pharmacol.* **2014**, *9*, 529-532.
- (16) Shelar, U. B. *Phytochemical And Pharmacological Study of Caesalpinia Decapetala Leaves*; M. K. Infoedutech Private Limited: India, **2022**. pp 1-171.
- (17) Charisiadis, P.; Kontogianni, V. G.; Tsiafoulis, C. G.; Tzakos, A. G.; Siskos, M.; Gerothanassis, I. P. *Molecules* **2014**, *19*, 13643-13682.
- (18) Hernández-García, E.; García, A.; Avalos-Alanís, F. G.; Rivas-Galindo, V. M.; Delgadillo-Puga, C.; Rayo Camacho-Corona, M. D. *Data Brief* **2018**, *22*, 255-268.
- (19) Cuong, T. D.; Hung, T. M.; Kim, J. C.; Kim, E. H.; Woo, M. H.; Choi, J. S.; Lee, J. H.; Min, B. S. *J. Nat. Prod.* **2012**, *75*, 2069-2075.
- (20) Cretin, B. N.; Sallembien, Q.; Sindt, L.; Daugey, N.; Buffeteau, T.; Waffo-Teguo, P.; Dubourdieu, D.; Marchal, A. *Anal. Chim. Acta* **2015**, *888*, 191-198.
- (21) Fu, J.; Liang, G. Y.; Zhang, J. X.; Zhang, Y. P.; Liu, L.; Pan, W. D.; Cao, P. X. *Xiandai Yaowu Yu Linchuang* **2013**, *28*, 265-268.
- (22) Jung, E. G.; Han, K. I.; Kwon, H. J.; Patnaik, B. B.; Kim, W. J.; Hur, G. M.; Nam, K. W.; Han, M. D. *Arch. Pharm. Res.* **2015**, *38*, 973-983.
- (23) Chang, T. S.; Chao, S. Y.; Ding, H. Y. *Int. J. Mol. Sci.* **2012**, *13*, 10359-10367.
- (24) Khlupova, M.; Vasil'eva, I.; Shumakovich, G.; Morozova, O.; Chertkov, V.; Shestakova, A.; Kisin, A.; Yeroplov, A. *J. Mol. Catal. B Enzym.* **2016**, *123*, 62-66.
- (25) Kim, J. S.; Kwon, Y. S.; Chun, W. J.; Kim, T. Y.; Sun, J.; Yu, C. Y.; Kim, M. J., *Food Chem.* **2010**, *120*, 539-543.
- (26) Kim, M. Y.; Chung, I. M.; Choi, D. C.; Park, H. J., *Nat. Prod. Sci.* **2009**, *15*, 208-212.
- (27) Abd El-Razek, M. H. *Asian J. Chem.* **2007**, *19*, 4867.
- (28) Namikoshi, M.; Nakata, H.; Yamada, H.; Nagai, M.; Saitoh, T. *Chem. Pharm. Bull.* **1987**, *35*, 2761-2773.
- (29) Verotta, L.; Dell'Agli, M.; Giolito, A.; Guerrini, M.; Cabalion, P.; Bosio, E. *J. Nat. Prod.* **2001**, *64*, 603-607.
- (30) Bohr, G.; Gerhäuser, C.; Knauff, J.; Zapp, J.; Becker, H. *J. Nat. Prod.* **2005**, *68*, 1545-1548.
- (31) Fawzi, F.; Mahdi, M. F.; Abaas, I. S. *J. Pharm. Sci.* **2019**, *11*, 185-190.

(32) Zhao, M. B.; Cai, C. Q.; Tu, P. F.; Tang, L. *Magn. Reson. Chem.* **2016**, *54*, 601-605.

(33) Ha, M. T.; Lee, T. H.; Kim, C. S.; Prajapati, R.; Kim, J. A.; Choi, J. S.; Min, B. S. *Phytochemistry* **2022**, *197*, 113100.

(34) Lee, S.; Choi, S. Y.; Choo, Y. Y.; Kim, O.; Tran, P. T.; Dao, C. T.; Min, B. S.; Lee, J. H. *Int. Immunopharmacol.* **2015**, *28*, 328-336.

(35) Proença, C.; Freitas, M.; Ribeiro, D.; Oliveira, E. F. T.; Sousa, J. L. C.; Tomé, S. M.; Ramos, M. J.; Silva, A. M. S.; Fernandes, P. A.;

Fernandes, E. *J. Enzyme Inhib. Med. Chem.* **2017**, *32*, 1216-1228.

(36) Arsiningtyas, I.; Kato, E.; Kawabata, J. *Planta Med.* **2015**, *81*, 42.

Received June 11, 2022

Revised August 16, 2022

Accepted September 6, 2022

**α -Glucosidase Inhibitory Activity of Phenolic Compounds Isolated
from the Stems of *Caesalpinia decapetala* var. *japonica***

**Thi Thanh Le¹, Manh Tuan Ha¹, Le Minh Hoang¹, Ngoc Khanh Vu¹, Jeong Ah Kim², and
Byung Sun Min^{1,*}**

¹*College of Pharmacy, Drug Research and Development Center, Daegu Catholic University,
Gyeongbuk 38430, Republic of Korea*

²*College of Pharmacy, Research Institute of Pharmaceutical Science, Kyungpook National
University, Daegu 41566, Republic of Korea*

*Corresponding author

Tel: +82 53 850 3613. Fax: +82 53 850 3602

Email address: bsmin@cu.ac.kr (B.S. Min)

Supporting information

Contents

Fig. S1. ^1H NMR spectrum of compound **1** (CD_3OD , 400 MHz).

Fig. S2. ^{13}C NMR spectrum of compound **1** (CD_3OD , 100 MHz).

Fig. S3. ^1H NMR spectrum of compound **2** (CD_3OD , 400 MHz).

Fig. S4. ^{13}C NMR spectrum of compound **2** (CD_3OD , 100 MHz).

Fig. S5. ^1H NMR spectrum of compound **3** (CD_3OD , 400 MHz).

Fig. S6. ^{13}C NMR spectrum of compound **3** (CD_3OD , 100 MHz).

Fig. S7. HMQC spectrum of compound **3**.

Fig. S8. HMBC spectrum of compound **3**.

Fig. S9. ^1H NMR spectrum of compound **4** (CD_3OD , 400 MHz).

Fig. S10. ^{13}C NMR spectrum of compound **4** (CD_3OD , 100 MHz).

Fig. S11. HMQC spectrum of compound **4**.

Fig. S12. HMBC spectrum of compound **4**.

Fig. S13. ^1H - ^1H COSY spectrum of compound **4**.

Fig. S14. ^1H NMR spectrum of compound **5** (CD_3OD , 400 MHz).

Fig. S15. ^{13}C NMR spectrum of compound **5** (CD_3OD , 100 MHz).

Fig. S16. ^1H NMR spectrum of compound **6** (CD_3OD , 400 MHz).

Fig. S17. ^{13}C NMR spectrum of compound **6** (CD_3OD , 100 MHz).

Fig. S18. ^1H NMR spectrum of compound **7** (CD_3OD , 400 MHz).

Fig. S19. ^{13}C NMR spectrum of compound **7** (CD_3OD , 100 MHz).

Fig. S20. ^1H NMR spectrum of compound **8** (CD_3OD , 400 MHz).

Fig. S21. ^{13}C NMR spectrum of compound **8** (CD_3OD , 100 MHz).

Fig. S22. ^1H NMR spectrum of compound **9** (CD_3OD , 400 MHz).

Fig. S23. ^{13}C NMR spectrum of compound **9** (CD_3OD , 100 MHz).

Fig. S24. ^1H NMR spectrum of compound **10** (CD_3OD , 400 MHz).

Fig. S25. ^{13}C NMR spectrum of compound **10** (CD_3OD , 100 MHz).

Fig. S26. ^1H NMR spectrum of compound **11** (CD_3OD , 400 MHz).

Fig. S27. ^{13}C NMR spectrum of compound **11** (CD_3OD , 100 MHz).

Fig. S28. ^1H NMR spectrum of compound **12** (CD_3OD , 400 MHz).

Fig. S29. ^{13}C NMR spectrum of compound **12** (CD_3OD , 100 MHz).

Fig. S30. ^1H NMR spectrum of compound **13** (DMSO, 400 MHz).

Fig. S31. ^{13}C NMR spectrum of compound **13** (DMSO, 100 MHz).

Fig. S32. ^1H NMR spectrum of compound **14** (CD_3OD , 400 MHz).

Fig. S33. ^{13}C NMR spectrum of compound **14** (CD_3OD , 100 MHz).

Fig. S34. ^1H NMR spectrum of compound **15** (CD_3OD , 400 MHz).

Fig. S35. ^{13}C NMR spectrum of compound **15** (CD_3OD , 100 MHz).

Fig. S36. ^1H NMR spectrum of compound **16** (CD_3OD , 400 MHz).

Fig. S37. ^{13}C NMR spectrum of compound **16** (CD_3OD , 100 MHz).

Fig. S38. ^1H NMR spectrum of compound **17/18** (CD_3OD , 400 MHz).

Fig. S39. ^{13}C NMR spectrum of compound **17/18** (CD_3OD , 100 MHz).

Fig. S1




Fig. S2.




Fig. S3.




Fig. S4.




Fig. S5.




Fig. S6.




Fig. S7.




Fig. S8.




Fig. S9.




Fig. S10.




Fig. S11.




Fig. S12.




Fig. S13.




Fig. S14.




Fig. S15.




Fig. S16.




Fig. S17.




Fig. S18.




Fig. S19.




Fig. S20.




Fig. S21.




Fig. S22.




Fig. S23.




Fig. S24.




Fig. S25.




Fig. S26.




Fig. S27.




Fig. S28.




Fig. S29.




Fig. S30.




Fig. S31.




Fig. S32.




Fig. S33.




Fig. S34.




Fig. S35.




Fig. S36.




Fig. S37.




Fig. S38.




Fig. S39.

